Clonally expanded CD38 hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor–associated arthritis
Authors:
- Runci WangRWRunci Wang
- Anvita SingarajuASAnvita Singaraju
- Kathryne E. MarksKMKathryne E. Marks
- Lorien ShakibLSLorien Shakib
- Garrett DunlapGDGarrett Dunlap
- Ifeoluwakiisi AdejoorinIAIfeoluwakiisi Adejoorin
- Stinne R. GreisenSGStinne R. Greisen
- Lin ChenLCLin Chen
- Aidan K. TirpackATAidan K. Tirpack
- Carlos AudeCACarlos Aude
- Miriam R. FeinMFMiriam R. Fein
- Derrick J. ToddDTDerrick J. Todd
- 28 July 2023
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (85) , eadd1591
Abstract
Immune checkpoint inhibitor (ICI) therapies used to treat cancer, such as anti–PD-1 antibodies, can induce autoimmune conditions in some individuals. The T cell mechanisms mediating such iatrogenic autoimmunity and their overlap with spontaneous autoimmune diseases remain unclear. Here, we compared T cells from the joints of 20 patients with an inflammatory arthritis induced by ICI therapy (ICI-arthritis) with two archetypal autoimmune arthritides, rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Single-cell transcriptomic and antigen receptor repertoire analyses highlighted clonal expansion of an activated effector CD8 T cell population in the joints and blood of patients with ICI-arthritis. These cells were identified as CD38 hi CD127 − CD8 T cells and were uniquely enriched in ICI-arthritis joints compared with RA and PsA and also displayed an elevated interferon signature. In vitro, type I interferon induced CD8 T cells to acquire the ICI-associated CD38 hi phenotype and enhanced cytotoxic function. In a cohort of patients with advanced melanoma, ICI therapy markedly expanded circulating CD38 hi CD127 − T cells, which were frequently bound by the therapeutic anti–PD-1 drug. In patients with ICI-arthritis, drug-bound CD8 T cells in circulation showed marked clonal overlap with drug-bound CD8 T cells from synovial fluid. These results suggest that ICI therapy directly targets CD8 T cells in patients who develop ICI-arthritis and induces an autoimmune pathology that is distinct from prototypical spontaneous autoimmune arthritides.Keywords
This publication has 64 references indexed in Scilit:
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal of Cancer, 2016
- T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infectionNature, 2015
- FlowSOM: Using self‐organizing maps for visualization and interpretation of cytometry dataCytometry Part A, 2015
- Regulation of type I interferon responsesNature Reviews Immunology, 2013
- Type I interferon is selectively required by dendritic cells for immune rejection of tumorsJournal of Experimental Medicine, 2011
- Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patientsAnnals of the Rheumatic Diseases, 2007
- A critical function for type I interferons in cancer immunoeditingNature Immunology, 2005
- Interleukin-6–dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family–independent survival pathway closely associated with Stat3 activationBlood, 2004
- Identification of NF-κB-regulated genes induced by TNFα utilizing expression profiling and RNA interferenceOncogene, 2003
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996